TargetBeta
PSMC2
proteasome 26S subunit, ATPase 2 · also MSS1, S7, Nbla10058, RPT1 · AAA ATPases
2 programs in company-led studies act on PSMC2, from 2 companies: 0 in phase 3, 2 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| Bortezomibrule | Johnson & Johnson | phase 4 | 8511 running | ADRM1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMC1, PSMC3, PSMC4, PSMC5, PSMC6, PSMD1, PSMD11, PSMD12, PSMD13, PSMD14, PSMD2, PSMD3, PSMD4, PSMD6, PSMD7, PSMD8, SEM1 | ChEMBL |
| carfilzomibrule | Amgen | phase 4 | 388 running | ADRM1, PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9, PSMC1, PSMC3, PSMC4, PSMC5, PSMC6, PSMD1, PSMD11, PSMD12, PSMD13, PSMD14, PSMD2, PSMD3, PSMD4, PSMD6, PSMD7, PSMD8, SEM1 | ChEMBL |
Also acted on by the same programs
Conditions their studies are in
- Amyloidosis, 2 programs
- Multiple Myeloma, 2 programs
- Carcinoma, Non-Small-Cell Lung, 1 program
- Lymphoma, Follicular, 1 program
- Lymphoma, Mantle-Cell, 1 program
- Ovarian Neoplasms, 1 program
- Small Cell Lung Carcinoma, 1 program
- Waldenstrom Macroglobulinemia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026carfilzomib · Amgen · phase 4 · NCT04973605
- Apr 5, 2027Bortezomib · Johnson & Johnson · phase 4 · NCT03319667
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.